Man Group
NKTR icon

Man Group’s Nektar Therapeutics NKTR Stock Holding History

Man Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Buy
+19,446
New +$1.11M ﹤0.01% 1719
2022
Q2 		– Sell
-1,344
Closed -$109K – 2300
2022
Q1 		$109K Buy
+1,344
New +$199K ﹤0.01% 2042
2021
Q2 		– Sell
-4,344
Closed -$1.3M – 2048
2021
Q1 		$1.3M Sell
4,344
-3,599
-45% -$1.12M 0.01% 1226
2020
Q4 		$2.02M Sell
7,943
-97
-1% -$25.1K 0.01% 1198
2020
Q3 		$2M Sell
8,040
-1,814
-18% -$571K 0.01% 1194
2020
Q2 		$3.42M Buy
+9,854
New +$3.07M 0.02% 841
2020
Q1 		– Sell
-3,873
Closed -$1.25M – 1789
2019
Q4 		$1.25M Sell
3,873
-9,391
-71% -$2.72M ﹤0.01% 1453
2019
Q3 		$3.62M Buy
13,264
+6,304
+91% +$2.31M 0.01% 1020
2019
Q2 		$3.71M Buy
6,960
+5,942
+584% +$2.98M 0.01% 1071
2019
Q1 		$513K Sell
1,018
-721
-41% -$427K ﹤0.01% 1727
2018
Q4 		$857K Sell
1,739
-12,475
-88% -$7.53M ﹤0.01% 1501
2018
Q3 		$13M Buy
14,214
+12,521
+740% +$10.7M 0.05% 497
2018
Q2 		$1.24M Sell
1,693
-440
-21% -$507K 0.01% 1540
2018
Q1 		$3.4M Buy
+2,133
New +$2.75M 0.02% 1053

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Man Group's NKTR Position: Q1 2026 in Review

Man Group opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 19,446 shares worth $1.4M. The stake represents ﹤0.01% of the portfolio and ranks #1719 among its holdings. This is a return to the name: Man Group previously reported a position in NKTR as recently as Q1 2022.

Man Group first reported a position in NKTR in Q1 2018 and has held it in 14 quarters since. The position peaked at $13M in Q3 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Man Group held 19,446 shares of Nektar Therapeutics worth $1.4M as of Q1 2026.
  • Nektar Therapeutics was a new Man Group position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1719 holding.
  • Man Group first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 14 quarters since.
  • Man Group's Nektar Therapeutics position peaked at $13M in Q3 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.